Q3 2012 Results (Vical) - Nov 7, 2012 - Anticipated results from P3 trial for melanoma in mid-2013
Anticipated P3 data • Melanoma
|
|
Allovectin
-- -- --
We continue to focus our efforts on our key development programs. Our top priority remains the completion of our Phase 3 trial of Allovectin. Based on the results of our recent sweep, we expect that our results to occur in mid 2013.
-- -- --
|